1139PDNovel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial. (23rd October 2018) - Wang, J; Liu, S V; Uronis, H E; Wu, C; Mahalingam, D; Spira, A; Carter, L; Hu, X; Weems, G; Wilkins, H J; Duska, L R; Kelly, K